Oncology

Certain antibiotics may have a more significant impact on CAR T-cell efficacy and toxicity.

AI may help to accurately classify pediatric sarcoma subtypes using digitized pathology images, potentially improving diagnosis and treatment accessibility across diverse health care settings.

Interim results from the phase 1 SENTI-202-101 trial show that SENTI-202, a logic-gated, off-the-shelf chimeric antigen receptor natural killer (CAR NK) cell therapy, achieved complete remission in 4 patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).

Pretrained foundation machine learning models significantly improved the accuracy of diagnosing non-melanoma skin cancer from digital pathology images and may offer a practical, resource-efficient solution for cancer diagnosis in underserved settings.

Zoldonrasib, a novel oral KRAS G12D-selective inhibitor, demonstrated promising safety and early antitumor activity in patients with previously treated non–small cell lung cancer (NSCLC), offering a potential new targeted therapy for this underserved population.

NCCN updates colon cancer guidelines, emphasizing testing for DPYD gene variants before initiating fluoropyrimidine-based chemotherapy.

This alternative to IV infusion reduces patient treatment times and eases providers’ operational burdens.

Pyrotinib is a tyrosine kinase inhibitor that is independently developed in China.

The treatment received indications as a monotherapy and in combination regimen with carboplatin or cisplatin and gemcitabine.

Ginger Blackmon, PharmD, explains how NCODA’s Positive Quality Interventions (PQIs) help improve oncology care by guiding best practices, supporting teamwork, and streamlining workflows.

The combination yielded superior progression-free (PFS) survival compared with standard of care.

Patients in both arms achieved statistically significant rates of compliance up to 97%.

The FDA approves zanidatamab for HER2-positive biliary cancer, improving treatment options.

PAK5 is a protein that drives resistance to trastuzumab emtansine in patients with HER2+ breast cancer.

Though new treatments offer hope, careful monitoring and understanding of risks remain essential for their success.

Obecabtagene autoleucel improves CAR T-cell therapy for B-cell ALL.

The Version 3.2025 update adds tislelizumab-based regimens as preferred first-line treatments and introduces new dosing schedules for PD-L1–positive esophageal squamous cell carcinoma.

Clinicians should not just focus on one single nucleotide polymorphism (SNP), but rather consider all SNPs because each factor causes unique adverse effects

Breast cancer treatment is highly individualized and based on the stage, hormone receptor status, HER2 expression, and patient-specific factors.

Continuing education supports pharmacy technician career advancement, retention, and skill development.

The meaningful results were reported in the DESTINY-Breast09 trial.

Delayed pegaspargase reduces hepatotoxicity without affecting outcomes.

Real-world data support momelotinib as an effective and well-tolerated treatment for myelofibrosis-related anemia.

The 2025 SPPCP Virtual Conference on Tuesday, May 20, 2025, will offer pharmacists and clinicians a full day of CE-accredited sessions on complex pain management, opioid use disorder, mentorship, and innovative approaches in palliative care, with opportunities for networking and professional development.

Sequencing of antibody-drug conjugates (ADCs) in HER2-mutated breast cancer is crucial for optimizing treatment outcomes.

Antibody-drug conjugates have revolutionized metastatic breast cancer treatment and classification.

Undetectable minimal residual disease rates improved with ongoing therapy.

The data showed improvements in overall response rates, progression-free survival, and duration of response.